Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
Nkarta Announces Clean Safety Profile for Cell Therapy Across Five Autoimmune Indications
Nkarta Announces Integrated Safety Results From 40 Patients Treated With NKX019, Allogeneic, Off-The-Shelf, CD19-Directed CAR NK Cell Therapy Candidate In Ongoing Ntrust Clinical Trial Program
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript
Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
Nkarta Reports Initial Clinical Data For NKX019 Demonstrating Early Efficacy And Favorable Tolerability In Autoimmune Disease Trial
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
Nkarta To Host Webcast On November 9 To Review Initial Clinical Data From Ntrust Program Evaluating NKX019 In Myositis And Systemic Sclerosis Being Presented At ACR Convergence 2026
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
Nkarta Q3 EPS $(0.45) Misses $(0.42) Estimate
HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta to Participate in September Investor Conferences
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders
Stifel Maintains Buy on Nkarta, Lowers Price Target to $10
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.